The Future of Cervical Cancer Prevention in Europe

Cervical cancer remains a significant source of disease and death in Europe. However, we now have the means to prevent virtually every case of cervical cancer through comprehensive, population-based, organised cervical cancer prevention programmes that effectively integrate cervical screening with the new technologies and vaccines that are now available. Given the potential health benefits of these programmes in reducing disease incidence and mortality, their establishment is now an ethical imperative for all European countries

Print information to inform decisions about mammography screening participation in 16 countries with population-based programs

OBJECTIVE: To profile and compare the content and presentation of written communications related to informed decision-making about mammography. METHODS: Materials from 16 screening programs organized at the national or regional level were analyzed according to five major information domains suggested by the international literature. RESULTS: A majority of countries provided information on the program (interval, cost and quality). There was considerable variability in comprehensiveness of elements in the domains, e.g., test characteristics (false positive/negative) and pros and cons of screening. The majority noted the likelihood of recall for further tests, few commented on the risks of additional tests or finding unimportant tumors. The audit also found variation in presentation (words and pictures). CONCLUSIONS: Presentation of comprehensive, but balanced information on screening benefits and risks is complex and daunting. Issues such as framing effects, coupled with debate about screening efficacy are challenging to the design of effective information tools. The objective of increasing screening prevalence at the population level must be balanced with objectively presenting complete and clear information. Additional research is needed on how information (and mode of presentation) impact screening decisions. PRACTICE IMPLICATIONS: Public health officials need to articulate their objectives and review written communication according to important decision-making domains. [Authors]]]> Decision Making ; Informed Consent ; Mammography ; Mass Screening ; Patient Acceptance of Health Care ; Patient Education as Topic oai:serval.unil.ch:BIB_E228BFDB52E0 2022-05-07T01:28:47Z openaire documents urnserval <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_E228BFDB52E0 Evaluation médico-économique de la thrombolyse de l'accident vasculaire cérébral hyperaigu par le rtPA (Actilyse) http://www.chuv.ch/bdfm/cdsp/MemoireBonvin.pdf Bonvin, Marielle Université de Lausanne, Faculté des hautes études commerciales masterthesis 2003 <![CDATA[L'AVC (accident vasculaire cérébral) représente la troisième cause de mortalité et la première cause de handicap fonctionnel chronique dans la population adulte occidentale. Son fardeau économique compte parmi les plus élevés de toutes les maladies. Ce mémoire a pour objet d'étudier l'impact économique d'une nouvelle procédure d'intervention, la thrombolyse des infarctus cérébraux par le rtPA, sur les coûts du Centre hospitalier universitaire vaudois. [Table des matières] 1. Introduction. 2. Physiopathologie et traitement de l'accident vasculaire cérébral : 2.1 Mécanismes de la coagulation sanguine 2.2 L'athérosclérose. 2.3 L'infarctus cérébral. 2.4 Les traitements de l'AVC. 2.5 La controverse. 2.6 La situation au CHUV. 2.7 Les enjeux économiques. 3. Méthodologie. 4. Tableaux : caractéristiques de l'échantillon et résultats. 5. Discussion. 6. Limites de l'étude. 7. Conclusion

Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma

The objective of the study was to evaluate the effect of neoadjuvant chemotherapy on the survival of patients with oropharyngeal cancer. Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy. The loco-regional treatment consisted either of surgery plus radiotherapy or of radiotherapy alone. Three cycles of chemotherapy consisting of Cisplatin (100 mg/m2) on day 1 followed by a 24-hour i.v. infusion of fluorouracil (1000 mg/m2/day) for 5 days were delivered every 21 days. 2–3 weeks after the end of chemotherapy, local treatment was performed. The trial was conducted by the Groupe d'Etude des Tumeurs de la Tête Et du Cou (GETTEC). A total of 318 patients were enrolled in the study between 1986 and 1992. Overall survival was significantly better (P = 0.03) in the neoadjuvant chemotherapy group than in the control group, with a median survival of 5.1 years versus 3.3 years in the no chemotherapy group. The effect of neoadjuvant chemotherapy on event-free survival was smaller and of borderline significance (P = 0.11). Stratification of the results on the type of local treatment, surgery plus radiotherapy or radiotherapy alone, did not reveal any heterogeneity in the effect of chemotherapy. © 2000 Cancer Research Campaign http://www.bjcancer.co

Occupation and skin cancer: the results of the HELIOS-I multicenter case-control study

<p>Abstract</p> <p>Background</p> <p>Non-melanoma skin cancer (NMSC) is the most frequent tumour among Caucasian populations worldwide. Among the risk factors associated with this tumour, there are host-related factors and several environmental agents. A greater likelihood of high exposure to physical agents (with the exception of solar radiation) and chemical agents depends on the work setting. Our objective is to evaluate the role of occupational exposures in NMSC, with special emphasis on risk factors other than solar radiation and skin type.</p> <p>Methods</p> <p>We analysed 1585 cases (1333 basal cell carcinoma (BCC) and 183 squamous cell carcinoma (SCC)) and 1507 controls drawn from the Helios-I multicenter study. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression mixed models.</p> <p>Results</p> <p>For NMSC as a whole (both <it>histological types</it>), miners and quarrymen, secondary education teachers, and masons registered excess risk, regardless of exposure to solar radiation and skin type (OR 7.04, 95% CI 2.44–20.31; OR 1.75, 95% CI 1.05–2.89 and OR 1.54, 95% CI 1.04–2.27, respectively). Frequency of BCC proved higher among railway engine drivers and firemen (OR 4.55; 95% CI 0.96–21.57), specialised farmers (OR 1.65; 95% CI 1.05–2.59) and salesmen (OR 3.02; 95% CI 1.05–2.86), in addition to miners and quarrymen and secondary education teachers (OR 7.96; 95% CI 2.72–23.23 and OR 1.76; 95% CI 1.05–2.94 respectively). The occupations that registered a higher risk of <it>SCC (though not of BCC</it>) were those involving direct contact with livestock, construction workers not elsewhere classified (OR 2.95, 95% CI 1.12–7.74), stationary engine and related equipment operators not elsewhere classified (OR 5.31, 95% CI 1.13–21.04) and masons (OR 2.55, 95% CI 1.36–4.78).</p> <p>Conclusion</p> <p>Exposure to hazardous air pollutants, arsenic, ionizing radiations and burns may explain a good part of the associations observed in this study. The Helios study affords an excellent opportunity for further in-depth study of physical and chemical agents and NMSC based on matrices of occupational exposure.</p

Projet de création d'un réseau de soins palliatifs dans le département de la Drôme (Texte imprimé)

MONTPELLIER-BU Médecine (341722104) / SudocMONTPELLIER-BU Médecine UPM (341722108) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

MESURE DE LA SURVIE DES PATIENTS CANCEREUX EN POPULATION A PARTIR DES REGISTRES DE CANCERS (INTERETS ET LIMITES (DOCTORAT : SANTE PUBLIQUE))

LE KREMLIN-B.- PARIS 11-BU Méd (940432101) / SudocPARIS-BIUM (751062103) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF

Dépistage de masse du cancer colo-rectal (application au département du Gard)

Le cancer est la deuxième cause de mortalité en France. Le cancer colo-rectal (CCR) est le deuxième cancer en fréquence, pour les deux sexes confondus. Les progrès thérapeutiques et les possibilités de prévention primaire sont insuffisants pour faire baisser la mortalité par CCR de manière significative. Quatre études européennes contrôlées (test Hemoccult II tous les deux ans chez les sujets de 50 à 74 ans) ont permis de démontrer l'efficacité du dépistage du CCR en terme de réduction de mortalité. En France, en 2000 a été lancé le plan national de lutte contre le cancer. Ce plan quinquennal a pour objectif la généralisation du dépistage des cancers du sein, du colon et du col de l'utérus. En ce qui concerne le cancer du colon, 20 départements pilotes (dont l'Hérault) mettent en place le dépistage organisé. Dans le Gard, les structures existantes pour le dépistage du cancer du sein devront évoluer pour la mise en place du dépistage du CCR.NANTES-BU Médecine pharmacie (441092101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF